Literature DB >> 10512276

Intravenous infusion of phenytoin relieves neuropathic pain: a randomized, double-blinded, placebo-controlled, crossover study.

G J McCleane1.   

Abstract

UNLABELLED: Neuropathic pain responds inconsistently to opioids and nonsteroidal antiinflammatory drugs. However, oral anticonvulsants have a proven analgesic effect on neuropathic pain, but may not be practical in an acute flare-up. Phenytoin was the first oral anticonvulsant used as an analgesic for neuropathic pain. There have been few studies on the parenteral analgesic effect of this drug. In this randomized, double-blind, placebo-controlled, crossover study of 20 patients with acute flare-ups of neuropathic pain, we compared a 2-h placebo infusion with a 2-h infusion of 15 mg/kg phenytoin. Overall pain, shooting pain, burning pain, paresthesia, numbness, and sensitivity were measured using a 10-cm linear visual analog score. Numbness and sensitivity were reduced in the placebo group during infusion, but not in the 7 days after infusion. In the phenytoin group, there were significant reductions in burning pain (P < 0.05), shooting pain (P < 0.001), sensitivity (P < 0.001), numbness (P < 0.05), and overall pain (P < 0.005) during the infusion period. The reduction in overall pain persisted for 1 day, in sensitivity for 2 days, and in shooting pain for 4 days after infusion. We conclude that IV infusion of 15 mg/kg phenytoin has an analgesic effect in acute flare-ups of neuropathic pain and that this relief outlives both the infusion time and plasma half-life of phenytoin. IMPLICATIONS: Oral phenytoin can relieve neuropathic pain. The aim of this study was to examine the effect of IV phenytoin on neuropathic pain. The results indicate that IV phenytoin may be used to treat flare-ups of chronic neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10512276     DOI: 10.1097/00000539-199910000-00030

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  13 in total

Review 1.  Pharmacological management of neuropathic pain.

Authors:  Gary McCleane
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Phenytoin for neuropathic pain and fibromyalgia in adults.

Authors:  Fraser Birse; Sheena Derry; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

3.  Small-cell lung cancer (human): potentiation of endocytic membrane activity by voltage-gated Na(+) channel expression in vitro.

Authors:  P U Onganer; M B A Djamgoz
Journal:  J Membr Biol       Date:  2005-03       Impact factor: 1.843

4.  Management of painful neuropathies.

Authors:  Harry J Gould
Journal:  Curr Treat Options Neurol       Date:  2007-03       Impact factor: 3.598

5.  Intravenous fosphenytoin for acute exacerbation of trigeminal neuralgia: case report and literature review.

Authors:  Alejandro Vargas; Kurian Thomas
Journal:  Ther Adv Neurol Disord       Date:  2015-07       Impact factor: 6.570

Review 6.  Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain.

Authors:  Alan B Ettinger; Charles E Argoff
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 7.  Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy.

Authors:  I W Tremont-Lukats; C Megeff; M M Backonja
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

Review 8.  Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy.

Authors:  Cecilie Johannessen Landmark
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 9.  Antiepileptic drugs in the treatment of neuropathic pain.

Authors:  Elon Eisenberg; Yaron River; Ala Shifrin; Norberto Krivoy
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 10.  Update on neuropathic pain treatment for trigeminal neuralgia. The pharmacological and surgical options.

Authors:  Khalid W Al-Quliti
Journal:  Neurosciences (Riyadh)       Date:  2015-04       Impact factor: 0.735

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.